BridgeMD

Sign in

Rectum Cancer clinical trials

Explore recruiting rectum cancer clinical trials.

Recruiting rectum cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Rectum Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy

France

Phase II and Phase III (Integrated) EU CTIS Study details

NEOadjuvant chemotherapy only compared with standard treatment for Locally Advanced Rectal cancer: a randomized phase II trial

Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING IN PATIENTS WITH BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OR SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB ( IMMUNE CHECKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Rectum Cancer trials by city

Rectum Cancer in Toronto Rectum Cancer in Vancouver Rectum Cancer in Montreal Rectum Cancer in Calgary Rectum Cancer in Edmonton Rectum Cancer in Ottawa Rectum Cancer in Winnipeg Rectum Cancer in Quebec City Rectum Cancer in Hamilton Rectum Cancer in Kitchener Rectum Cancer in London Rectum Cancer in Halifax Rectum Cancer in New York Rectum Cancer in Los Angeles Rectum Cancer in Chicago Rectum Cancer in Houston